Table 1.
Ongoing phase II/III target trials in advanced gastric cancer
| Study | Line | Control arm | Experimental arm | Target | NCT number |
| JACOB | 1st | Placebo + | Pertuzumab + | HER2 | NCT01774786 |
| Trastuzumab + | Trastuzumab + | ||||
| Chemotherapy | Chemotherapy | ||||
| ID NUMBER:11-166 | 2nd | - | Afatinib + | HER2 | NCT01522768 |
| Paclitaxel | |||||
| NIEGA | 2nd | - | Irinotecan + | EGFR | NCT03400592 |
| Nimotuzumab | |||||
| ENRICH | 2nd | Irinotecan | Irinotecan + | EGFR | NCT01813253 |
| Nimotuzumab | |||||
| CheckMate-649 | 1st | Oxaliplatin + | - Nivolumab + Oxaliplatin + | PD-1, CTLA-4 | NCT02872116 |
| Fluoropyrimidine | |||||
| Fluoropyrimidine | |||||
| - Ipilimumab + Nivolumab | |||||
| ATTRACTION-4 | 1st | Placebo + Oxaliplatin + S-1/Capecitabine | Oxaliplatin + S-1/Capecitabine + Nivolumab | PD-1 | NCT02746796 |
| JAVELIN Gastric 100 | 1st | Maintenance 1st line | Avelumab | PD-L1 | NCT02625610 |
| KEYNOTE-062 | 1st | Platin/fluoropyrimidine | - Pembrolizumab | PD-1 | NCT02494583 |
| - Pembrolizumab + Platin/fluoropyrimidine | |||||
| SPOTLIGHT | 1st | Oxaliplatin + | Zolbetuximab + Oxaliplatin + | CLDN18.2 | NCT03504397 |
| Fluoropyrimidine | Fluoropyrimidine | ||||
| ILUSTRO | 1st/3rd | - | - Zolbetuximab monotherapy, 3rd line | CLDN18.2 | NCT03505320 |
| - Zolbetuximab + FOLFOX, 1st line | |||||
| GLOW | 1st | Oxaliplatin + | Zolbetuximab + Oxaliplatin + | CLDN18.2 | NCT03653507 |
| Capecitabine | Capecitabine | ||||
| ANGEL | 3rd | BSC | Apatinib | VEGFR-2 | NCT03042611 |
| INTEGRATE II | 3rd | Placebo | Regorafenib | VEGFR1-3, | NCT02773524 |
| FGFR, | |||||
| PDGFR-β RAF, RET and KIT |
JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Gastroesophageal Junction or Gastric Cancer; ID NUMBER:11-1669: Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer; NIEGA: Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma; ENRICH: Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer; CheckMate649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer; ATTRACTION-4: Study of ONO-4538 in Gastric Cancer; JAVELIN: Gastric 100Avelumab in First-Line Maintenance Gastric Cancer; KEYNOTE-062: Study of Pembrolizumab as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; SPOTLIGHT: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction Cancer; ILUSTRO: A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab in Participants With Claudin 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction Adenocarcinoma; GLOW: A Study of Zolbetuximab Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; ANGEL: Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer; INTEGRATEII: A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer, Best supportive care; HER2: Human epidermal growth factor receptor 2; EGFR: Epidermal growth factor receptor; PD-L1: Programmed death ligand 1; PD-1: Programmed cell death protein 1; CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; CLDN18.2: Claudine-18.2; VEGFR1-3: Vascular endothelial growth factor receptor 1-3; FGFR: Fibroblastic growth factor receptor; PDGFR-β: Platelet-derived growth factor receptor beta; RAF: Serine/threonine-specific protein kinases RAF; RET: Rearranged during transfection; KIT: Tyrosine-protein kinase Kit.